Table 1.

Median post‐vaccination immunoglobulin (Ig)G and median fold increase of antibody level post‐ over prevaccination for serotypes 3, 4 and 9N with level of statistical significance for the difference between groups [Kruskal–Wallis one‐way analysis of variance (anova) and Dunn's post‐hoc test].

			2–5 years		≥ 10 years
			1998–2005 (n = 159)	2010–12 (n = 240)	1998–2005 (n = 112)	2010–12 (n = 58)	1998–2005 versus 2010–12		2–5 versus ≥ 10 years
Median age (Q1–Q3)	Serotype	PCV‐7	3 years (3–4)	3 years (3–4)	31 years (15–47)	30 years (16–47)	2–5 years	≥ 10 years	1998–2005	2010–12
Median IgG post‐vaccination (Q1–Q3) (mg/l)	3	–	2·7 (0·9–5·0)	4·2 (2·4–7·7)	2·1 (0·9–4·3)	2·4 (1·2–4·3)	***	n.s.	n.s.	***
	9N	–	3·8 (1·6–7·1)	9·6 (4·7–19·2)	5·4 (2·4–9·7)	3·6 (1·8–11·6)	***	n.s.	n.s.	***
	4	+	3·3 (1·5–4·8)	14·6 (7·9–21·0)	4·0 (1·7–5·6)	1·7 (1·1–5·5)	***	n.s.	n.s.	***
Median fold increase IgG (Q1–Q3)	3	–	8·9 (1·5–34·5)	5·0 (1·7–11·5)	2·2 (1·3–4·7)	2·1 (1·4–2·9)	*	n.s.	***	***
	9N	–	7·8 (2·9–21)	16·7 (6·9–34·2)	2·1 (1·5–5·3)	6·0 (1·7–14·8)	***	*	***	***
	4	+	10·6 (5·0–21·8)	18·5 (10·2–30·1)	2·5 (1·4–6·5)	3·4 (1·5–8·2)	***	n.s.	***	***

Only 2–5‐year‐old children tested in 2010–12 were vaccinated with PCV‐7 (grey column). PCV = pneumococcal conjugate vaccine; n = the number of included subjects; Q1 and Q3 = first and third quartiles; n.s. = not significant. *P‐value between 0·01 and 0·05; **P‐value between 0·001 and 0·01; *** P‐value < 0·001.